DGAP-News: STRATEC reports on first three months of 2016 (news with additional features)


DGAP-News: STRATEC Biomedical AG / Key word(s): Quarterly / Interim
Statement/Quarter Results
STRATEC reports on first three months of 2016 (news with additional
features)

26.04.2016 / 07:36
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

STRATEC reports on first three months of 2016

Birkenfeld, April 26, 2016

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,
TecDAX) today comments on its business performance and major events in the
period from January 1, 2016 through to March 31, 2016 with the publication
of its Quarterly Statement Q1|2016.

In the first quarter of 2016, STRATEC laid important foundations for its
future. With the acquisition of the hematology specialist Diatron as of
March 31, 2016, STRATEC has substantially boosted its ranges of in-vitro
diagnostics products and services and expects to benefit from development,
production, and procurement synergies, while also generating notable growth
momentum in a market segment the company had previously not occupied.
Before announcing this acquisition, STRATEC reported in March that the most
recent customer forecasts received gave reason to expect a very weak first
quarter of 2016 and also adjusted its medium-term company forecast to
annual organic growth averaging 6% through to 2017. An updated forecast,
extended to include future sales and earnings at Diatron, is expected to be
published with the half-yearly financial report 2016 and will account for
the impact of STRATEC's acquisition activities. Diatron was acquired as of
March 31, 2016. Its sales for the months of April to December 2016 will
therefore be included in STRATEC's group figures for the 2016 financial
year. The STRATEC Group's profitability prior to integration costs is
expected to remain virtually unchanged on the previous year.

STRATEC generated total sales of EUR 31.2 million in the first three months
of 2016 (previous year: EUR 34.5 million). The company achieved EBIT of EUR
4.5 million (previous year: EUR 5.8 million) and consolidated net income of
EUR 3.4 million (previous year: EUR 4.7 million).

Given its positive growth outlook, STRATEC expanded its workforce to 595
employees in the first quarter of 2016, up by 48 employees compared with
the previous year (excluding impact of Diatron takeover).

In view of the record results achieved in the 2015 financial year and given
the company's ongoing strong business prospects, the Board of Management
and Supervisory Board decided to propose the company's twelfth consecutive
dividend increase, in this case to EUR 0.75, for approval by the Annual
General Meeting on June 9, 2016 (previous year: EUR 0.70).

 
Major key figures

<pre>
EUR thousands              01.01.- 03.31.2016  01.01.- 03.31.2015    Change
Sales                                  31,218              34,547     -9.6%
EBIT                                    4,530               5,840    -22.4%
Consolidated net income                 3,424               4,739    -27.7%
Earnings per share (EUR)                 0.29                0.40    -28.1%
EBIT margin (%)                          14,5                16,9  -240 bps
</pre>


Business performance
STRATEC expects its organic sales to grow to between EUR 150 million and
EUR 154 million in the current 2016 financial year. Consistent with
expectations, however, sales during the first quarter showed a year-on-year
reduction of 9.6% to EUR 31.2 million. As already communicated on March 15,
2016, this was due to a weaker performance in the instrumentation business,
and in particular to the Asian business at one of the company's partners
falling short of expectations. Sales in other areas showed stable
developments.

Given a stable share of sales generated with service parts and a slight
decline in the number of analyzer systems supplied, the consistently high
level of development expenses resulting from the company's full development
pipeline had a corresponding impact on the EBIT margin, which amounted to
14.5% at the end of the first three months of 2016 (previous year: 16.9%).
This resulted in consolidated net income of EUR 3.4 million (-27.7%;
previous year: EUR 4.7 million). Earnings per share amounted to EUR 0.29
(-28.1%; previous year: EUR 0.40).

Acquisition of Diatron
On April 1, 2016, STRATEC announced the completion of Diatron, a Budapest,
Hungary based company that designs and produces system solutions for the
fields of hematology and clinical chemistry in particular, as well as
associated consumables. Diatron was founded more than 25 years ago and
supplies analyzer systems and complementary products, such as consumables
and services, for application in human and veterinary diagnostics to more
than 100 countries. Its customers include prestigious global life science
players. In the past 2015 financial year, Diatron generated sales
equivalent to around EUR 34 million with profitability comparable to the
STRATEC Group's. The acquisition is expected to result in a positive
earnings contribution in the current year already. Diatron has around 200
employees, mainly working in development, production, and sales, at
locations in Hungary and the US. The company's development and production
of systems and solutions in Budapest, Hungary, meet all regulatory
requirements for all major markets. STRATEC expects to generate synergies,
particularly in the development and production of consumables, modules for
complete analyzer systems, and smaller systems. Diatron's platform-based
development method and its OEM partnership-based market access structure
are both similar to STRATEC's approach. The systems offered by Diatron are
especially suited for countries whose healthcare systems are highly
decentralized in terms of their organization, as is often the case in
emerging and developing economies.

Development in personnel
The total number of employees at the STRATEC Group, including personnel
hired from a temporary employment agency and trainees, grew year-on-year by
9.0% from 546 to 595 as of March 31, 2016. Given ongoing demand from our
partners for our research and development services and for analyzer
systems, we continue to seek for well-qualified personnel, especially in
the development division.

Projects and other developments
STRATEC is focusing on achieving key development milestones, upcoming
market launches, and finalizing negotiations for new development and
production contracts. Another key focus is on developing proprietary
platform solutions that will contribute to the company's further growth
from 2017 onwards.

Expanding production and development capacities is also an important factor
in the company's plans for its future growth. The move to new premises at
STRATEC's site in Romania is scheduled to take place by the middle of the
year. The new building section expanding production capacities at the
location in Beringen, Switzerland, was officially opened in the first
quarter and is already in use.

Current financial forecast and outlook
Even though at the beginning of the year STRATEC's partners in individual
cases submitted skeptical reports about market developments, especially in
Asia, the company has now received several more optimistic assessments. The
development pipeline and market launches by STRATEC's partners in the
coming quarter, together with test volumes in the diagnostics industry
gives grounds to continue to expect a positive business performance.
Consistent with the current financial forecast for the financial years from
2014 to 2017, the company expects to generate annual average sales growth
of around 6%. For the current 2016 financial year, STRATEC expects its
sales to grow to between EUR 150 million and EUR 154 million. The EBIT
margin, which due to the product mix has recently risen faster than
originally planned, should be maintained in the current year at around the
level achieved in 2015. This forecast has not yet been updated to account
for the Diatron acquisition executed as of March 31, 2016. This new
subsidiary will be consolidated as of the acquisition date on March 31,
2016. An updated financial forecast accounting for the impact of
acquisition activities is expected to be issued upon publication of the
half-yearly financial report on July 21, 2016.

2016 Annual General Meeting
At their meeting on April 11, 2016, the Board of Management and Supervisory
Board of STRATEC Biomedical AG decided to propose the payment of a dividend
of EUR 0.75 per share for the 2015 financial year for approval by the
Annual General Meeting on June 9, 2016 (distribution in previous year: EUR
0.70 per share). Based on the current total of 11,846,280 shares with
dividend entitlement, the proposal corresponds to a 7.7% increase in the
distribution total to EUR 8.9 million (previous year: EUR 8.2 million).
STRATEC has a continuity-based dividend policy. If approved, this year's
dividend would be the twelfth consecutive increase in the distribution to
shareholders since dividends were first paid in 2004.

 
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com


+++++
Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=BLBFKKPELL
Document title: STRATEC Quarterly Statement Q1|2016

---------------------------------------------------------------------------

26.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------


   Language:    English                                                     
   Company:     STRATEC Biomedical AG                                       
                Gewerbestr. 37                                              
                75217 Birkenfeld                                            
                Germany                                                     
   Phone:       +49 (0)7082 7916 0                                          
   Fax:         +49 (0)7082 7916 999                                        
   E-mail:      info@stratec.com                                            
   Internet:    www.stratec.com                                             
   ISIN:        DE000STRA555                                                
   WKN:         STRA55                                                      
   Indices:     TecDAX                                                      
   Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated   
                Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,  
                Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX    
 
 
   End of News    DGAP News Service  
---------------------------------------------------------------------------

457427 26.04.2016
GlobeNewswire